2-(5-Bromopyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole 2,2-difluoroacetate 、 氨 在
乙酸乙酯 、 hexanes 作用下,
反应 0.25h,
以to give 113 mg of the title compound as a white solid的产率得到3-bromo-5-(5-(difluoromethyl)-4H-1,2,4-triazol-3-yl)pyridine
参考文献:
名称:
HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211
[EN] HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211<br/>[FR] DÉRIVÉS D'URÉE HÉTÉROCYCLIQUE ET LEURS PROCÉDÉS D'UTILISATION-211
申请人:ASTRAZENECA AB
公开号:WO2009106885A1
公开(公告)日:2009-09-03
Chemical Compounds Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
[EN] HETEROCYCLIC UREA DERIVATIVES USEFUL FOR TREATMENT OF BACTERIAL INFECTION<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES DE L'URÉE UTILES POUR LE TRAITEMENT D'UNE INFECTION BACTÉRIENNE
申请人:ASTRAZENECA AB
公开号:WO2011024004A1
公开(公告)日:2011-03-03
Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211
申请人:Bist Shanta
公开号:US20120101100A1
公开(公告)日:2012-04-26
Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.